These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38874196)

  • 41. The Current Status of the Liver Liquid Biopsy in MASH Related HCC: Overview and Future Directions.
    Ugonabo O; Udoh US; Rajan PK; Reeves H; Arcand C; Nakafuku Y; Joshi T; Finley R; Pierre SV; Sanabria JR
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759769
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolic Risks Are Increasing in Non-B Non-C Early-Stage Hepatocellular Carcinoma: A 10-Year Follow-Up Study.
    Lin YP; Wang PM; Chuang CH; Yong CC; Liu YW; Huang PY; Yao CC; Tsai MC
    Front Oncol; 2022; 12():816472. PubMed ID: 35186751
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sarcopenia Imperils Postoperative Long-Term Survival in HCC Patients with Metabolic Dysfunction-Associated Fatty Liver Disease: A Propensity Score Matching Analysis.
    Kong Q; Yi M; Teng F; Li H; Chen Z
    J Hepatocell Carcinoma; 2023; 10():1367-1377. PubMed ID: 37605756
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes.
    Ito T; Nguyen MH
    J Hepatocell Carcinoma; 2023; 10():413-428. PubMed ID: 36926055
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sex Differences in the Impact of Metabolic Dysfunction-associated Fatty Liver Disease on the of Patients with Hepatocellular Carcinoma After Radical Resection.
    Huang J; Wei S; Tang Y; Zhang Q; Luo H; Tang Z; Tang Y; Liu H; Huang W; Dong X; Yang J
    J Cancer; 2023; 14(7):1107-1116. PubMed ID: 37215444
    [No Abstract]   [Full Text] [Related]  

  • 46. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
    Wu J
    Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD).
    Zhao Y; Zhou Y; Wang D; Huang Z; Xiao X; Zheng Q; Li S; Long D; Feng L
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139341
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH).
    Gallego-Durán R; Albillos A; Ampuero J; Arechederra M; Bañares R; Blas-García A; Berná G; Caparrós E; Delgado TC; Falcón-Pérez JM; Francés R; Fernández-Barrena MG; Graupera I; Iruzubieta P; Nevzorova YA; Nogueiras R; Macías RIR; Martín F; Sabio G; Soriano G; Vaquero J; Cubero FJ; Gracia-Sancho J
    Gastroenterol Hepatol; 2022 Nov; 45(9):724-734. PubMed ID: 35248669
    [TBL] [Abstract][Full Text] [Related]  

  • 49. From MAFLD to hepatocellular carcinoma and everything in between.
    Bae SDW; George J; Qiao L
    Chin Med J (Engl); 2022 Feb; 135(5):547-556. PubMed ID: 35191421
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genetic predisposition in metabolic-dysfunction-associated fatty liver disease and cardiovascular outcomes-Systematic review.
    Ismaiel A; Dumitrascu DL
    Eur J Clin Invest; 2020 Oct; 50(10):e13331. PubMed ID: 32589269
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma.
    Green CD; Weigel C; Brown RDR; Bedossa P; Dozmorov M; Sanyal AJ; Spiegel S
    FASEB J; 2022 Jul; 36(7):e22372. PubMed ID: 35639028
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Obesity-associated mechanisms of hepatocarcinogenesis.
    Karagozian R; Derdák Z; Baffy G
    Metabolism; 2014 May; 63(5):607-17. PubMed ID: 24629562
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MASLD-Related HCC-Update on Pathogenesis and Current Treatment Options.
    Leyh C; Coombes JD; Schmidt HH; Canbay A; Manka PP; Best J
    J Pers Med; 2024 Mar; 14(4):. PubMed ID: 38672997
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of MAFLD on HBV-Related Stage 0/A Hepatocellular Carcinoma after Curative Resection.
    Lin YP; Lin SH; Wang CC; Lin CC; Chen DW; Chuang CH; Huang PY; Hung CH; Yang SY; Cho WR; Chen YS; Tsai MC
    J Pers Med; 2021 Jul; 11(8):. PubMed ID: 34442328
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features.
    Zhu C; Ho YJ; Salomao MA; Dapito DH; Bartolome A; Schwabe RF; Lee JS; Lowe SW; Pajvani UB
    J Hepatol; 2021 Mar; 74(3):613-626. PubMed ID: 33038431
    [TBL] [Abstract][Full Text] [Related]  

  • 56. From MASH to HCC: the role of Gas6/TAM receptors.
    Apostolo D; Ferreira LL; Vincenzi F; Vercellino N; Minisini R; Latini F; Ferrari B; Burlone ME; Pirisi M; Bellan M
    Front Immunol; 2024; 15():1332818. PubMed ID: 38298195
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study.
    Chen YG; Yang CW; Chung CH; Ho CL; Chen WL; Chien WC
    Hepatol Int; 2022 Aug; 16(4):807-816. PubMed ID: 35064545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Outcomes of Liver Transplantation in Severe Metabolic Dysfunction-Associated Steatotic Liver Disease Patients.
    Paklar N; Mijic M; Filipec-Kanizaj T
    Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002096
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Innate immunity and nonalcoholic fatty liver disease.
    Kountouras J; Kazakos E; Kyrailidi F; Polyzos SA; Zavos C; Arapoglou S; Boziki M; Mouratidou MC; Tzitiridou-Chatzopoulou M; Chatzopoulos D; Doulberis M; Papaefthymiou A; Vardaka E
    Ann Gastroenterol; 2023; 36(3):244-256. PubMed ID: 37144011
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cholesterol Metabolism: A Double-Edged Sword in Hepatocellular Carcinoma.
    Zhou F; Sun X
    Front Cell Dev Biol; 2021; 9():762828. PubMed ID: 34869352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.